摘要
目的 :探讨氯沙坦和胰激肽释放酶联合治疗糖尿病肾病的疗效。方法 :6 0例患者随机分为两组 (各 30例 ) ,对照组采用饮食控制降血糖及氯沙坦治疗 ,治疗组在对照组基础上加用胰激肽释放酶 ,疗程共 8周 ,观察治疗前后两组的尿微量白蛋白 (AL B)、尿微球蛋白 (β2 - MG)、尿糖蛋白 (THP)及平均动脉压 (MAP)等指标。结果 :总有效率治疗组为 96 .6 7% ,对照组为 83.33% ,两组比较有显著性差异 (P <0 .0 5 ) ;各指标治疗后均不同程度降低 ,治疗组尿微量白蛋白 (AL B)、尿微球蛋白 (β2 - MG)、尿糖蛋白 (THP)治疗前后及与对照组治疗后比较有显著性差异 (P <0 .0 1)、对照组治疗前后有明显差异 (P <0 .0 5 ) ;血压两组治疗前后有明显差异 (P <0 .0 1) ,治疗组与对照组治疗后比较无差异 (P >0 .0 5 )。结论 :氯沙坦和胰激肽释放酶联合治疗糖尿病肾病能明显控制尿蛋白 ,减轻肾功能损害 。
Objective:To explore the curative effect of integrated Losartan and Kallikrein on diabetic nephropathy(DN) Methods:Sixty patients with DN were randomly divided into two groups,the treatment groups(30 cases) was treated with Kallikrein,on the basis of controlling blood glucose with medicine.30 patients in th control group were treated with Losartan.The course of treatment was eight week.The urinary micro protein series(urinary albumin,Tamm horsfall protein and β 2 microglobulin) and mean arterial blood pressure (MAP) were observed before and after treatment Results:The total effective rate in the treatment group was 96 67% while that in the control group was 83 33%,the difference between two groups was significant (P<0 05).The related parameters,including urinary albumin,Tamm horsfall,protein β 2 microglobulin and MAP were all improved after treatment in the treatment group and the control group (P<0 01 or P<0 05).After treatment,MAP was insignificance between the control group and treatment group (P>0 05) Conclusion:Losartan and Kallikrein could lower urinary micro protein,decrease kidney damage,therefore,it show a better effect in treating diabetic nephropathy
出处
《广西医学》
CAS
2003年第2期182-184,共3页
Guangxi Medical Journal
